Form D · Pharmaceuticals
Orexigen Therapeutics, Inc.
La Jolla, CA · CIK 0001382911
Offering snapshot reported Mar 3, 2017 · SEC filing
- Reported sold
- $49.6M Offering amount: $49.6M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 3, 2017 | Initial | $49,597,000 | No comparison | 9 | SEC filing |
| Mar 29, 2016 | Initial | $165,000,000 | No comparison | 21 | SEC filing |
| Sep 15, 2015 | Initial | $60,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.55M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-281701
Issuance of $49,597,000 in original principal amount of 2.75% Convertible Exchange Senior Notes due 2020 (the "New Notes") in exchange for $49,597,000 in original principal amount of 2.75% Convertible Senior Notes due 2020 (the "Existing Notes").
Represents a fee of $1,477,916 and $75,000 of expenses.
Source: Form D, filed Mar 3, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Heather Ace | Executive |
| Louis C Bock | Director |
| Thomas Cannell | Executive |
| Wendy L Dixon | Director |
| Brian H. Dovey | Director |
| David J Endicott | Director |
| Peter Flynn | Executive |
| Joseph Hagan | Executive |
| Peter K Honig | Director |
| Deborah Jorn | Director |
| Jason Keyes | Executive |
| Preston Klassen | Executive |
| Thomas Lynch | Executive |
| Patrick J Mahaffy | Director |
| Michael Narachi | Director, Executive |
| Eckard Weber | Director |
| Lota S Zoth | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3344 N. Torrey Pines Ct. Suite 200
La Jolla, CA, 92037
La Jolla, CA, 92037